When considering what names to put on your watch list, focus on stocks with an 80 or higher RS Rating. Tempus AI now meets that criteria, with an increase from 78 to 82 Friday.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's unique RS Rating measures market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the trailing 52 weeks matches up against other publicly traded companies.
Decades of market research reveals that the market's biggest winners typically have an RS Rating of over 80 as they launch their biggest climbs.
Tempus AI is trying to complete a cup without handle with a 74.83 buy point. See if the stock can clear the breakout price in volume at least 40% higher than normal.
Tempus AI reported 0% EPS growth in the latest quarterly report. Revenue increased 90%.
The company holds the No. 3 rank among its peers in the Medical-Research Equipment/Services industry group. Medpace Holdings is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
